PTK2 and cancer: Although the most promising FAK inhibitor, Defactinib, has been approved for combination therapy with Avutometinib in low-grade serous ovarian cancer, it has not shown clear efficacy in clinical trials for other cancers, including NSCLC[20,22,23].